ZIOPHARM Oncology Presents Systemic, DNA/Cell Plasmid Therapy Showing Long-Term Persistence and Anti-Tumor Effects at EORTC-NCI-AACR Meeting

[at noodls] – NEW YORK, Nov. 7, 2012 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today … more

View todays social media effects on ZIOP

View the latest stocks trending across Twitter. Click to view dashboard